Drug Prices

In this week's Democratic presidential debate, Senators Elizabeth Warren of Massachusetts and Amy Klobuchar of Minnesota said they could, and would, take executive action to reduce prices for much-needed drugs as president.

Major U.S. pharmaceutical companies are set to increase the prices of some of their most popular prescription drugs, including the breast cancer medication Ibrance.

The bill seemingly began as a bipartisan effort, but with little GOP support it faces an uphill battle in the Senate.

Imagine if travel websites listed flights with no prices, as airline companies argued that they simply can't know the price before you fly.

China and our other economic competitors would love to see us undermine our own domestic biopharmaceutical sector to their benefit.

"For too long American patients have been paying exorbitantly high prices for prescription drugs that are made available to other countries at lower prices," Azar said in a statement on Wednesday.

Trump promised to lower drug prices but he won't take on the manufacturers. When Americans buy drugs, they really buy advertising and political influence-peddling.

The SEC has allowed pharma CEOS to block shareholder resolutions that seek detail on price increases for major medicines.

Marathon Pharmaceuticals' newly approved drug is now on hold after patient advocates and policymakers criticized its expensive price.

46 million Americans have insurance deductibles of $1,000 a year or greater.

Without laws to enforce them, the president's ideas to control drug prices will do just the opposite.

An EpiPen cost $100 in 2008, but the price rose to $600 in 2016.

Government price fixing will produce unintended consequences in drug research and pricing.

Just as value is required in other industries, so should be the case in health care.

Bean-counting over drug costs ought to be abhorrent to anyone who calls himself a physician.

New cancer drugs can extend life for days, months, even years. But they can also push you and your family into bankruptcy.

The California agency that runs the state's Obamacare marketplace is limiting the cost of high-end medicine.